STOCK TITAN

Vivani Medical agrees to about $5.1M private placement

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Vivani Medical, Inc. (VANI) agreed to sell 5,049,506 common shares at $1.01 per share to entities affiliated with board Chairman Gregg Williams and director Aaron Mendelsohn. The private placement is expected to generate approximately $5.1 million in gross proceeds before estimated offering expenses; it includes no warrants or discounts, and no placement-agent or investment-banking fees were incurred. Priced “at-the-market” under Nasdaq rules, the transaction is expected to close on or about November 23, 2026, subject to customary closing conditions.

Vivani intends to use net proceeds for research and clinical development of NPM-139 and other product candidates, working capital and general corporate purposes. It anticipates proceeds plus existing cash, cash equivalents and restricted cash will fund operations into the third quarter of 2027. In the four-week, open-label Phase 1 SLIM-1 trial of 20 participants, no NPM-139 recipients experienced treatment-related adverse events; 5 of 10 Wegovy controls did, all gastrointestinal. No serious adverse events were reported. Vivani said these results support advancing NPM-139 toward a Phase 2 dose-ranging weight-maintenance trial anticipated to begin in 2027.

Filing Explained

Item 1.01’s proceeds wording sounds completed, but the release leaves closing conditional.

Vivani agreed to sell 5,049,506 new shares, which would reduce existing holders’ percentage ownership if issued; the release places closing around November 23, 2026, subject to customary conditions.

That pending-close account conflicts with Item 1.01’s statement that the placement “resulted” in about $5.1 million in gross proceeds; the release instead calls the proceeds expected, so receipt is not established.

Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 3.02 Unregistered Sales of Equity Securities Securities
The company sold equity securities in a private placement or other unregistered transaction.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Private placement shares 5,049,506 shares Common shares Vivani agreed to sell
Purchase price $1.01 per share Private placement price
Expected gross proceeds Approximately $5.1 million Before estimated offering expenses
Expected closing On or about November 23, 2026 Subject to customary closing conditions
Expected operating runway Into the third quarter of 2027 Expected using proceeds together with existing cash, cash equivalents and restricted cash
SLIM-1 participants 20 participants Four-week Phase 1 trial
NPM-139 participants with treatment-related adverse events 0 of 10 participants SLIM-1 trial
Wegovy controls with treatment-related adverse events 5 of 10 participants All reported events were gastrointestinal
Rule 506 of Regulation D regulatory
"exemption from registration under Rule 506 of Regulation D"
Rule 506 of Regulation D is a U.S. Securities and Exchange Commission exemption that lets companies sell securities privately without registering them with the SEC, similar to a private party invitation rather than a public auction. It matters to investors because it determines how much information they’ll receive, who can buy (accredited vs. non-accredited), whether public advertising is allowed, and how easily the investment can be resold — all factors that affect risk, transparency and liquidity.
Section 4(a)(2) regulatory
"exemption from registration afforded by Section 4(a)(2)"
Section 4(a)(2) is a part of U.S. securities laws that allows companies to sell their stock directly to certain investors without registering the sale with regulators. This process is often used for private placements, making it easier and faster for companies to raise money from knowledgeable or institutional investors. It matters to investors because it provides an alternative way to buy shares, often with fewer disclosures and lower costs.
at-the-market financial
"priced “at-the-market” under the rules and regulations"
"At-the-market" is a method for companies to sell new shares of stock directly into the open market over time, rather than all at once. It allows companies to raise money gradually, similar to selling slices of a pie instead of the entire pie at once, which can help manage the sale's impact on the stock price. This approach gives investors a steady supply of shares while providing companies with flexible funding options.
open-label medical
"four-week, open-label, active-controlled trial"
Open-label describes a situation where everyone involved in a study or process knows the full details, such as who is receiving a treatment or intervention. For investors, understanding whether a project or product is open-label helps gauge the level of transparency and potential biases, influencing trust and decision-making. It’s like knowing whether a test or experiment is conducted openly or behind closed doors.
dose-ranging medical
"Phase 2 dose-ranging weight maintenance trial"
A dose-ranging study is a clinical trial that tests multiple amounts of a drug to find what dose works best and is safest, much like trying different spice levels in a recipe to get the right balance. For investors, results clarify whether a medicine is effective at practical doses, how likely it is to win regulatory approval, what side effects to expect, and how the treatment might be priced and used in the market.
NanoPortal™ platform technical
"Leveraging its proprietary NanoPortal™ platform"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares are included in VANI’s private placement, and at what price?

Vivani agreed to sell 5,049,506 shares of common stock at $1.01 per share to entities affiliated with Chairman Gregg Williams and director Aaron Mendelsohn. The purchase price matched the common stock’s last reported sale price on November 13, 2026.

When is VANI’s private placement expected to close?

The transaction is expected to close on or about November 23, 2026, subject to the satisfaction of customary closing conditions.

Are the shares in VANI’s private placement registered?

No. The shares are unregistered and are being sold to accredited investors in reliance on Section 4(a)(2) and Rule 506 of Regulation D. They may not be offered or sold in the United States absent registration or an applicable exemption under securities laws.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001266806 false00012668062026-11-152026-11-15

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 15, 2026

 

 

Vivani Medical, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-36747

 

02-0692322

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

1350 S. Loop Road

Alameda, California

 

94502

(Address of principal executive offices)

(Zip Code)

 

Registrant’s telephone number, including area code: (415) 506-8462

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

VANI

 

The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 



Item 1.01 Entry into a Material Definitive Agreement.

Private Placement

Vivani Medical, Inc. (the “Company”) entered into a Share Purchase Agreement, dated November 15, 2026 (the “Purchase Agreement”), with entities affiliated with Gregg Williams, Chairman of the Company’s board of directors, and Aaron Mendelsohn, another member of the Company’s board of directors (collectively, the “Purchasers”) for the purchase of an aggregate of 5,049,506 shares of common stock, par value of $0.0001 per share (“Common Stock”) of the Company at a purchase price of $1.01 per share (the “Private Placement Shares”), the last reported sale price of the Common Stock on November 13, 2026.  This private placement of Common Stock resulted in gross proceeds of approximately $5.1 million to the Company.  No warrants or discounts were provided and no placement agent or investment banking fees were incurred in connection with the private placement.

The Private Placement Shares will be issued pursuant to an exemption from registration under Rule 506 of Regulation D, which is promulgated under the Securities Act of 1933, as amended (the “Securities Act”).  The Company relied on this exemption from registration based in part on representations made by each of the Purchasers.

The above description of principal terms of the Purchase Agreement is qualified in its entirety by reference to that agreement attached hereto as Exhibit 10.1.

Item 3.02 Unregistered Sales of Equity Securities.

Pursuant to the private placement described in Item 1.01 of this Current Report on Form 8-K, which description is incorporated by reference into this Item 3.02 in its entirety, the Company has agreed to sell the Private Placement Shares to “accredited investors,” as that term is defined in the Securities Act, in reliance on the exemption from registration afforded by Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated under the Securities Act and corresponding provisions of state securities or “blue sky” laws.  Each Purchaser represented that it is acquiring the Private Placement Shares for investment only and not with a view towards, or for, resale in connection with, the public sale or distribution thereof.  Accordingly, the Private Placement Shares have not been registered under the Securities Act and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act and any applicable state securities laws.  Neither this Current Report on Form 8-K nor any exhibit attached hereto is an offer to sell or the solicitation of an offer to buy shares of common stock or other securities of the Company.

Item 7.01 Regulation FD Disclosure

Private Placement Press Release

On November 16, 2026, the Company issued a press release titled “Vivani Medical Announces Private Placement Equity Offering.” The press release is furnished hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. 

Corporate Presentation

The Company from time to time presents and/or distributes to the investment community at various industry and other conferences slide presentations to provide updates and summaries of its business. These slides are attached to this Current Report as Exhibit 99.2 and are incorporated by reference herein. The Company is also posting to the “Investors” portion of its website a copy of its current corporate slide presentation. The slides speak as of the date of this Current Report on Form 8-K. While the Company may elect to update the slides in the future or reflect events and circumstances occurring or existing after the date of this Current Report, the Company specifically disclaims any obligation to do so.

The information contained in this Current Report on Form 8-K under Item 7.01, including the attached Exhibits 99.1 and 99.2, is being furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section.  The information contained in this Current Report on Form 8-K under Item 7.01, shall not be incorporated by reference into any filing under the Securities Act, or any filing under the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

10.1*

Share Purchase Agreement, dated as of November 15, 2026.

99.1

Press Release issued November 16, 2026.

99.2

Vivani Medical, Inc. slide presentation dated November 16, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

* Filed herewith.

 



SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

VIVANI MEDICAL, INC.

 

 

 

Date: November 16, 2026

By:

/s/ Donald Dwyer

 

Name:

Donald Dwyer

 

Title:

Chief Business Officer

 



Exhibit 99.1

 

 

ALAMEDA, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced a private placement of 5,049,506 shares of its common stock at an offering price of $1.01 per share purchased by Gregg Williams, the Chairman of the Company’s board of directors, and Aaron Mendelsohn, another member of the Company’s board of directors, pursuant to a Share Purchase Agreement dated November 15, 2026. The gross proceeds to the Company from the private placement are expected to be approximately $5.1 million, before estimated offering expenses. The financing follows the Company’s November 12, 2026 announcement of positive top-line results from SLIM-1, its first-in-human Phase 1 clinical trial of NPM-139, which support advancing NPM-139 toward a Phase 2 dose-ranging weight maintenance trial anticipated to begin in 2027.

SLIM-1 was a four-week, open-label, active-controlled trial in 20 otherwise healthy overweight or obese participants, with 10 receiving low-dose NPM-139 and 10 receiving the starting dose of Wegovy (0.25 mg/week semaglutide injection). No NPM-139 participants experienced adverse events reported as treatment related. Five of 10 Wegovy control group participants experienced adverse events reported as treatment related, all of which were gastrointestinal. No serious adverse events were reported in the study, and implant insertions and removals were brief and successfully completed without complications.

The private placement was priced “at-the-market” under the rules and regulations of The Nasdaq Stock Market LLC. The private placement is expected to close on or about November 23, 2026, subject to the satisfaction of customary closing conditions.

The Company intends to use the net proceeds from the private placement to fund ongoing research and clinical development of its semaglutide implant, NPM-139, and the Company’s other product candidates, as well as for working capital and general corporate purposes. The Company anticipates that the net proceeds from the offering, together with its existing cash, cash equivalents and restricted cash, will fund the Company’s operations into the third quarter of 2027.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About Vivani Medical, Inc.

Leveraging its proprietary NanoPortal™ platform, Vivani develops miniature, biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence and improving patient tolerance to their medication. Vivani is developing a portfolio of GLP-1 based implants for metabolic diseases including obesity and type 2 diabetes. These NanoPortal implants are designed for once- or twice-yearly administration to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the numerous challenges associated with the daily or weekly administration of orals and injectables, including tolerability issues and loss of efficacy. Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarming number of patients, approximately 50%, including those taking daily pills. 

Forward-Looking Statements

This press release contains certain “forward-looking statements” within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” and other similar expressions that are used in this press release, including statements regarding Vivani’s business, products in development, including the therapeutic potential or the planned development thereof, and its technology, strategy, cash position and financial runway, and the closing of the private placement. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Vivani’s current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Vivani’s control. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including, without limitation, risks of unexpected costs or delays, and risks and uncertainties associated with the development and commercialization of products and product candidates that may impact or alter anticipated business plans, strategies and objectives. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Vivani’s expectations in any forward-looking statement. There may be additional risks that the Company considers immaterial, or which are unknown. A further list and description of risks and uncertainties are more fully described in periodic filings with the U.S. Securities and Exchange Commission (the “SEC”) including the factors described in Vivani’s most recent Quarterly Report on Form 10-Q filed with the SEC on November 12, 2026, as updated by future filings with the SEC. Any forward-looking statement made by Vivani in this press release is based only on information currently available to the Company and speaks only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of added information, future developments or otherwise, except as required by law.

Company Contact:
Donald Dwyer
Chief Business Officer
info@vivani.com
(415) 506-8462

 

Investor and Media Relations Contact:
Jami Taylor
Investor and Media Relations Advisor
investors@vivani.com
(415) 506-8462

 

Exhibit 99.2

Graphics



Graphics



Graphics



Graphics



Graphics



Graphics

 



Graphics



Graphics



Graphics



Graphics



Graphics



Graphics

 



Graphics

 



Graphics

 



Graphics

 



Graphics

 



Graphics

 



Graphics

 



Graphics

 



Graphics

 



Graphics

 



Graphics

 



Graphics

 



Graphics

 



Graphics

 



Graphics

 



Graphics

 



Graphics

 



Graphics

 



Graphics

 



Graphics

 



Graphics

 



Graphics

 



Graphics

 



Graphics

 


Filing Exhibits & Attachments

8 documents

Keep reading